Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2024 Dec 26;15(1):133-142.
doi: 10.34172/apb.43798. eCollection 2025 Apr.

An Optimized Method for Single Cell Cloning of Human CAR-T Cells Based on FBS-Coated Plates

Affiliations

An Optimized Method for Single Cell Cloning of Human CAR-T Cells Based on FBS-Coated Plates

Mahdie Jafari et al. Adv Pharm Bull. .

Abstract

Purpose: T cell-based immunotherapy, especially chimeric antigen receptor (CAR)-T cells, has emerged as an appropriate approach for treating hematologic malignancies and is currently under investigation in clinical trials for solid tumors. Despite significant improvements in CAR-T cell production processes, the isolation and expansion of CAR-engineered T cells continue to pose significant challenges. The aim of this research is to provide a simple and cost-effective method for the isolation and expansion of human CAR-T cells. This novel concept applies coated fetal bovine serum (FBS) culture plates and focuses on enhancing viability and functionality to improve the adherence of suspended T cells.

Methods: This study evaluated a two-dimensional (2D) culture technique for isolating the CAR-T cells that target prostate-specific membrane antigen (PSMA) utilizing matrices pre-coated with 0.2% glutaraldehyde and FBS. Jurkat cells were transduced with a lentiviral vector encoding the anti-PSMA CAR construct. FBS-coated and commercialized Matrigel-coated matrices were used for single-cell isolation and clonal expansion. Functional tests were conducted to assess the activation and proliferation of CAR-T cells and the IFN-γ release assay subsequent to cloning and expansion.

Results: Transfection efficiency markedly improved, with 88.4% of Lenti-X 293T cells demonstrating green fluorescent protein (GFP) expression. Among the Jurkat cells, 57.1% showed GFP expression post-transduction, of which 34.1% showed surface expression of anti-PSMA CAR. Clonal expansion on the FBS-coated matrix proved effective, yielding 92.1% GFP-positive isolated cells. Functional assays demonstrated that CAR-T cells co-cultured with LNCaP cells exhibited significantly enhanced proliferation, activation (as indicated by CD69 and CD25 expression), and cytokine release assay (IFN-γ) compared with those co-cultured with DU 145 and mock cells.

Conclusion: This new approach is efficient, economical, and scalable for isolating specific homogenous T cells and promoting their clonal proliferation and expansion. Furthermore, this method improves T cell adherence, proliferation, and functional effectiveness, offering a potential foundation for advancing CAR-T cell therapies aimed at solid tumors. Future research should concentrate on optimizing culture conditions and testing this method in preclinical animal models to ensure its clinical applicability and efficacy.

Keywords: 2D culture system; CAR-T cells; Cancer immunotherapy; Clonal expansion; FBS coating; Single cell isolation.

PubMed Disclaimer

Conflict of interest statement

The authors declare that they have no conflict of interest.

Figures

Figure 1
Figure 1
Figure 2
Figure 2
Figure 3
Figure 3
Figure 4
Figure 4
Figure 5
Figure 5

Similar articles

References

    1. Feins S, Kong W, Williams EF, Milone MC, Fraietta JA. An introduction to chimeric antigen receptor (CAR) T-cell immunotherapy for human cancer. Am J Hematol. 2019;94(S1):S3–9. doi: 10.1002/ajh.25418. - DOI - PubMed
    1. Mody H, Ogasawara K, Zhu X, Miles D, Shastri PN, Gokemeijer J, et al. Best practices and considerations for clinical pharmacology and pharmacometric aspects for optimal development of CAR-T and TCR-T cell therapies: an industry perspective. Clin PharmacolTher. 2023;114(3):530–57. doi: 10.1002/cpt.2986. - DOI - PubMed
    1. Larson RC, Maus MV. Recent advances and discoveries in the mechanisms and functions of CAR T cells. Nat Rev Cancer. 2021;21(3):145–61. doi: 10.1038/s41568-020-00323-z. - DOI - PMC - PubMed
    1. Jafari M, Kadkhodazadeh M, Bahrololoumi Shapourabadi M, Hashemi Goradel N, Shokrgozar MA, Arashkia A, et al. Immunovirotherapy: the role of antibody-based therapeutics combination with oncolytic viruses. Front Immunol. 2022;13:1012806. doi: 10.3389/fimmu.2022.1012806. - DOI - PMC - PubMed
    1. Mariotti S, Nisini R. Generation of human T cell clones. Methods Mol Biol. 2009;514:65–93. doi: 10.1007/978-1-60327-527-9_6. - DOI - PubMed

LinkOut - more resources